EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunogenicity of monovalent and multivalent subunit vaccines against SARS-CoV-2 variants in mice with divergent vaccination history

Rui Wang, Yuan Lyu iD, Meng Chen, Lili Sun, Shaozheng Zhou, Yudi Cui, Juan Ma, Desheng Kong, Jianbo Lu, Xuefeng Li, Liangzhi Xie iD

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.02907-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Rui Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, China. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19 Vaccines, COVID-19, Immunogenicity, Vaccine. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There are challenges in selecting SARS-CoV-2 vaccine compositions, primarily due to divergent infection or vaccination history and immunological biases toward previous strains. In this study, we evaluated humoral immune responses induced by variant-based monovalent vaccines as booster shots in mice previously vaccinated with an ancestral strain-based vaccine with or without Omicron BA.5 exposure. Our data suggest that immunological biases toward earlier variants attenuated the potency of variant-based vaccines as a booster dose against subsequent variants, whereas a second booster dose mitigated this effect. Furthermore, in the context of vaccine-induced immunity, prior exposure to Omicron sublineages (e.g., BA.5) attenuated the effect of immunological biases toward earlier variants on the neutralizing potency against Omicron subvariants. In addition, the interval between vaccine doses should also be considered, as an immunologic plateau might occur after repeated vaccination. Furthermore, the XBB.1 monovalent vaccine and a tetravalent vaccine (SCTV01E-2) composed of pre-Omicron variant (Beta) and Omicron subvariants (BA.1, BQ.1.1, and XBB.1) showed comparable neutralizing potency against several Omicron sublineages (BA.1, BA.5, BQ.1.1, XBB.1, XBB.1.5, XBB.1.16, and EG.5) under divergent vaccination history, implicating that multivalent platforms could be explored as a flexible strategy if future strains diverge significantly from current variants. IMPORTANCE Continuous evolution of SARS-CoV-2 variants has raised the need to optimize immunization regimens and update vaccine compositions to protect against the newly emerging variants in the context of repeated vaccination. The significance of this research is briefly summarized as follows: 1) Immunological biases toward earlier variants attenuated the potency of variant-based vaccines as a booster dose against subsequent variants, which can be mitigated by a second booster dose. 2) In the context of vaccine-induced immunity, a previous exposure to Omicron sublineages, such as BA.5, attenuated the influence of immunological biases toward earlier variants on the neutralizing potency against Omicron subvariants. 3) The interval between vaccine doses should be taken into account since an immunologic plateau might occur after repeated vaccination. 4) Multivalent vaccines, with epitope diversity, may theoretically enhance the magnitude and breadth of cross-neutralization responses, thereby providing a buffer for unpredictable future variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19 VaccinesCOVID-19Immunogenicity, VaccineAnimalsMiceAntibodies, NeutralizingAntibodies, ViralVaccines, SubunitVaccinationFemaleImmunization, SecondaryHumansMice, Inbred BALB CSpike Glycoprotein, Coronavirus

Stichwörter der Autor:innen

SARS-CoV-2monovalent vaccinesmultivalent vaccinesvaccine-induced immunity

Substanzen

COVID-19 VaccinesAntibodies, NeutralizingAntibodies, ViralVaccines, SubunitSpike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, China.
  • Beijing Key Laboratory of Monoclonal Antibody Research and Development, Sino Biological Inc., Beijing, China.
  • Cell Culture Engineering Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

ORCID-Profile: Yuan Lyu, Liangzhi Xie

Zitieren

APA

Wang, R., Lyu, Y., Chen, M., Sun, L., Zhou, S., Cui, Y., Ma, J., Kong, D., Lu, J., Li, X., & Xie, L. (2025). Immunogenicity of monovalent and multivalent subunit vaccines against SARS-CoV-2 variants in mice with divergent vaccination history. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02907-24

Vancouver

Wang R, Lyu Y, Chen M, Sun L, Zhou S, Cui Y, et al. Immunogenicity of monovalent and multivalent subunit vaccines against SARS-CoV-2 variants in mice with divergent vaccination history. Microbiology Spectrum. 2025. doi:10.1128/spectrum.02907-24

BibTeX
@article{Wang2025,
  author = {Wang, Rui and Lyu, Yuan and Chen, Meng and Sun, Lili and Zhou, Shaozheng and Cui, Yudi and Ma, Juan and Kong, Desheng and Lu, Jianbo and Li, Xuefeng and Xie, Liangzhi},
  title = {Immunogenicity of monovalent and multivalent subunit vaccines against SARS-CoV-2 variants in mice with divergent vaccination history},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.02907-24}
}
Kostenlos starten →